{rfName}
Wh

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Colomer RAuthorMondéjar RAuthorRomero-Laorden NAuthorAlfranca AAuthorSanchez-Madrid FAuthorQuintela-Fandino MAuthor

Share

Publications
>
Review

When should we order a next generation sequencing test in a patient with cancer?

Publicated to:EClinicalMedicine. 25 100487-100487 - 2020-08-01 25(), DOI: 10.1016/j.eclinm.2020.100487

Authors: Colomer, Ramon; Mondejar, Rebeca; Romero-Laorden, Nuria; Alfranca, Arantzazu; Sanchez-Madrid, Francisco; Quintela-Fandino, Miguel

Affiliations

Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. - Author
Ctr Nacl Invest Oncol CNIO, Madrid, Spain - Author
Departament of Medicine, Universidad Autónoma de Madrid (UAM), Spain. - Author
Endowed Chair of Personalised Precision Medicine, Universidad Autónoma de Madrid (UAM)-Fundación Instituto Roche, Spain. - Author
Hosp Univ La Princesa, Immunol Div, Madrid, Spain - Author
Hosp Univ La Princesa, Med Oncol Div, Madrid, Spain - Author
Hosp Univ Quiron, Med Oncol Div, Pozuelo De Alarcon Madri, Spain - Author
Immunology Division, Hospital Universitario La Princesa, Madrid, Spain. - Author
Medical Oncology Division, Hospital Universitario La Princesa, Madrid, Spain. - Author
Medical Oncology Division, Hospital Universitario Quirón, Pozuelo de Alarcón - Madrid, Spain. - Author
Univ Autonoma Madrid UAM, Dept Med, Madrid, Spain - Author
Univ Autonoma Madrid UAM, Endowed Chair Personalised Precis Med, Fdn Inst Roche, Madrid, Spain - Author
See more

Abstract

Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.© 2020 The Author(s).

Keywords

Cancer genomicsCancer therapyNext generation sequencingPersonalised medicinePrecision oncologyTargeted therapy

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal EClinicalMedicine due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 8.12, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 32.91 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-29, the following number of citations:

  • WoS: 103
  • Scopus: 112
  • Europe PMC: 70
  • Google Scholar: 149

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-29:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 213.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 232 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 61.55.
  • The number of mentions on the social network X (formerly Twitter): 16 (Altmetric).
  • The number of mentions on Wikipedia: 1 (Altmetric).
  • The number of mentions in news outlets: 6 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/696022

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (COLOMER BOSCH, RAMON) and Last Author (QUINTELA FANDIÑO, MIGUEL ANGEL).